Diamedica Therapeutics Stock Performance
| DMAC Stock | USD 4.95 0.03 0.60% |
The firm shows a Beta (market volatility) of 0.22, which means not very significant fluctuations relative to the market. As returns on the market increase, DiaMedica Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding DiaMedica Therapeutics is expected to be smaller as well. At this point, DiaMedica Therapeutics has a negative expected return of -0.0403%. Please make sure to confirm DiaMedica Therapeutics' mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if DiaMedica Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, DiaMedica Therapeutics is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 4.5 M | |
| Free Cash Flow | -22.1 M |
DiaMedica |
DiaMedica Therapeutics Relative Risk vs. Return Landscape
If you would invest 526.00 in DiaMedica Therapeutics on December 24, 2024 and sell it today you would lose (31.00) from holding DiaMedica Therapeutics or give up 5.89% of portfolio value over 90 days. DiaMedica Therapeutics is currently does not generate positive expected returns and assumes 3.4419% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than DiaMedica, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DiaMedica Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DiaMedica Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DiaMedica Therapeutics, and traders can use it to determine the average amount a DiaMedica Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0117
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DMAC |
Estimated Market Risk
| 3.44 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average DiaMedica Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DiaMedica Therapeutics by adding DiaMedica Therapeutics to a well-diversified portfolio.
DiaMedica Therapeutics Fundamentals Growth
DiaMedica Stock prices reflect investors' perceptions of the future prospects and financial health of DiaMedica Therapeutics, and DiaMedica Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DiaMedica Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 167.47 M | ||||
| Shares Outstanding | 42.86 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 5.19 X | ||||
| EBITDA | (26.64 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Book Value Per Share | 0.95 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Earnings Per Share | (0.60) X | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
About DiaMedica Therapeutics Performance
By analyzing DiaMedica Therapeutics' fundamental ratios, stakeholders can gain valuable insights into DiaMedica Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DiaMedica Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DiaMedica Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Things to note about DiaMedica Therapeutics performance evaluation
Checking the ongoing alerts about DiaMedica Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DiaMedica Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DiaMedica Therapeutics generated a negative expected return over the last 90 days | |
| DiaMedica Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| Roughly 26.0% of the company shares are held by company insiders |
- Analyzing DiaMedica Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DiaMedica Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining DiaMedica Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DiaMedica Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DiaMedica Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DiaMedica Therapeutics' stock. These opinions can provide insight into DiaMedica Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |